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Structural and functional details of the N-terminal
activation function 1 (AF1) of most nuclear receptors
are poorly understood due to the highly dynamic
intrinsically disordered nature of this domain. A
hydrogen/deuterium exchange (HDX) mass-spec-
trometry-based investigation of TATA box-binding
protein (TBP) interaction with various domains
of progesterone receptor (PR) demonstrate that
agonist-bound PR interaction with TBP via AF1
impacts the mobility of the C-terminal AF2. Results
from HDX and other biophysical studies involving
agonist- and antagonist-bound full-length PR and
isolated PR domains reveal the molecular mecha-
nism underlying synergistic transcriptional activation
mediated by AF1 and AF2, dominance of PR-B iso-
form over PR-A, and the necessity of AF2 for full
AF1-mediated transcriptional activity. These results
provide a comprehensive picture elaborating the
underlying mechanism of PR-TBP interactions as a
model for studying nuclear receptor (NR)-transcrip-
tion factor functional interactions.
INTRODUCTION
The progesterone receptor (PR) is the cognate steroid receptor
(SR) for the hormone progesterone belonging to the nuclear re-
ceptor (NR) superfamily. This receptor plays a pivotal role in a
range of biological functions, including development and main-
tenance of female reproductive tissue (Anderson and Clarke,
2004; Graham and Clarke, 1997; Li and O’Malley, 2003; Obr
and Edwards, 2012). There are two major isoforms of PR,
PR-A and PR-B, with the latter having extra 164 amino acids at
the N terminus. For a majority of PR target genes, PR-B is a
more potent transcriptional activator as compared to PR-A
(Tung et al., 1993; Vegeto et al., 1993). The functional differences
and tissue specificity of both isoforms are evident from knockout
studies in mice (Fernandez-Valdivia et al., 2005). It has been re-
ported that, in breast cancer cells, the majority of PR targetStructure 22genes are regulated by the B isoform (Mote et al., 1999, 2002;
Richer et al., 2002).
Steroid NRs are multidomain proteins containing an N-termi-
nal domain (NTD), DNA-binding domain (DBD), hinge region,
and a C-terminal ligand-binding domain (LBD). Both the LBD
and DBD of PR and other SRs are globular in nature, and they
have been well studied by a wide range of structural techniques.
Moreover, several cocrystal structures of ligand-bound LBD in
complex with coregulatory peptides have been solved (Bledsoe
et al., 2002; Brzozowski et al., 1997; Madauss et al., 2007; Raaij-
makers et al., 2009; Shiau et al., 1998;Williams and Sigler, 1998).
Typical of SRs, PR consists of an unusually large intrinsically
disordered (ID) NTD that comprises nearly half of the receptor.
PR contains two activation function domains (AF1 and AF2)
that provide interaction surfaces for transcriptional coregulatory
proteins to bind. The N-terminal AF1 is ligand-independent,
whereas the C-terminal AF2 is ligand-dependent. Unfortunately,
no high-resolution structures of full-length SRs have been re-
ported, partly due to the highly disordered nature of their NTDs
(Hill et al., 2012; Khan et al., 2012; Kumar and McEwan, 2012;
Kumar and Thompson, 2012; McEwan et al., 2007). Thus, efforts
to develop steroid receptor modulators (SRMs) for endocrine-
based therapies have been mostly based on their ability to
modulate AF2/LBD surfaces for coregulatory protein interac-
tions, thus neglecting the AF1/NTD despite the fact that this re-
gion of SRs contributes significantly to the transcriptional activity
of these receptors.
Despite the lack of defined structure, ID regions of proteins are
known to play important roles in molecular recognition and
assembly formations. They carry out functions through a pro-
cess called coupled binding and folding, where upon interaction
with its target binding partner, the ID protein or region undergoes
a disorder-ordered transition (Dyson and Wright, 2002; Wright
andDyson, 2009). Consistent with this, a core C-terminal domain
of the transcription factor TBP (TBPc; amino acids [aas] 159–339)
has been reported to bind and fold the AF1/NTD regions of
several SRs by promoting the ordered structure formation that
facilitates AF1-mediated activity (Khan et al., 2011; Kumar
et al., 2004, 2013; Wa¨rnmark et al., 2001). In a recent report,
we demonstrated a subregion of PR AF1/NTD (aas 350–428) is
required for TBPc binding and TBPc-dependent PR transcrip-
tional activation (Kumar et al., 2013). However, these previous
studies have examined the influence of TBP on structure and, 961–973, July 8, 2014 ª2014 Elsevier Ltd All rights reserved 961
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HDX of TBP PR activationfolding of isolated NTDs and thus do not account for mecha-
nisms and potential conformational flexibility associated with
interdomain interactions of full-length receptors. It has been sug-
gested that SRs are dynamic ensembles of structures respond-
ing to a variety of target molecules via synergistic actions of AF1
and AF2. Both the AFs are regulated through allosteric coupling
to produce differential selection and/or activation of gene
expression (Billas and Moras, 2013; Hilser and Thompson,
2011). However, direct detection of coordinated actions of AF1
and AF2 to bring about synergistic effects on gene activation re-
mains elusive (Tetel et al., 1999; Tung et al., 2006).
Because AF1/NTDs have eluded crystallization and no high-
resolution structures have been obtained of intact SRs, several
groups have applied solution phase techniques to study SR
structures, including the use of hydrogen/deuterium exchange
mass spectrometry (HDX-MS). HDX-MS has emerged as a
powerful technique to characterize conformational flexibility
associated with protein-protein or protein-ligand interaction in
solution state (Chalmers et al., 2006; Englander, 2006; Koner-
mann et al., 2011; Landgraf et al., 2013; Zhang et al., 2014).
HDX-MS has advantages for large molecular proteins such as
SRs because it is not limited by protein size and can localize
changes in conformational flexibility to specific sequences.
This technique has been used previously to characterize NRs’
interaction with other binding partners and small-molecule-
dependent activation mechanisms (Chalmers et al., 2011; Dai
et al., 2009; Devarakonda et al., 2011; Goswami et al., 2013;
Harms et al., 2013; Zhang et al., 2011). Here, we report the
use of HDX-MS to provide an analysis of the solution state flex-
ibility of full-length PR-A and PR-B and the conformational
ensemble of PR upon binding the coregulatory protein TBP
and hormonal agonist and antagonist ligands. These studies
demonstrate that, although TBP directly binds PR through
AF1/NTD, conformational rearrangements in the intact PR
involve both AF1/NTD and AF2/LBD, indicating intramolecular
interdomain interactions. Changes in structural flexibility in re-
gions of TBP were also observed upon interaction with PR-
NTD/AF1, indicating the potential of the NTD/AF1 to modulate
conformation and activity of coregulatory proteins.
RESULTS
Sequence Coverage of Full-Length Progesterone
Receptor
Intact PR-A and PR-B complexed with either hormone agonist
ligand (R5020) or antagonist (RU486) were expressed in the
baculovirus insect cell system and purified to near homogeneity
as previously described (Kumar et al., 2013; Wardell et al., 2005).
Purified full-length PR-A and PR-B have previously been shown
by biochemical and biophysical analyses to form dimers in solu-
tion in the absence of DNA (Connaghan-Jones et al., 2006;
Heneghan et al., 2005; Tetel et al., 1997). By size-exclusion chro-
matography, purified PR-A and PR-B in the 1 or 2 mM range used
here for HDX analysis behaved as a stable dimeric protein
(data not shown). Pepsin digestion of PR-A (750 aa) and
PR-B (930 aa) liganded with R5020 under HDX compatible
conditions resulted in 75% and 78% sequence coverage,
respectively (Figure S1A available online). Whereas sequence
coverage of the LBD was nearly complete, sequence coverage962 Structure 22, 961–973, July 8, 2014 ª2014 Elsevier Ltd All rightsof the heavily posttranscriptionally modified (including phos-
phorylation, acetylation, methylation, and others) AF1/NTD was
significantly less (59% PR-A; 69% PR-B). Sequence coverage
for PR-A was similar to that previously reported whereas this
report is of HDX-MS of the larger full-length PR-B (Kumar et
al., 2013). As anticipated, sequence coverage decreased slightly
as the perturbation map (Figure S1B) contains only peptides that
are detected in all the injections (all 45 injections for a three-repli-
cate experiment). Nevertheless, the overall sequence coverage
is sufficient to provide meaningful insight into the flexibility of
such large proteins in the 85–100 kDa range.
Conformational Flexibility of Full-Length PR and TBPc
We investigated the conformational flexibility of full-length PR-A
and PR-B bound to the hormone agonist R5020, and the results
are displayed in Figure 1 (also Figures S2 and S3). The average
percentage deuterium exchange corrected for back exchange
(see Experimental Procedures) over a 1 hr time period is overlaid
onto the crystal structure of PR-LBD (Protein Data Bank [PDB]
ID: 1A28) and PRDBD (PDB ID: 2C7A). Because no crystal struc-
ture is available containing the NTD and hinge for either PR-A or
PR-B, these regions are illustrated schematically. The exchange
dynamics of agonist-bound PR-B and PR-A are displayed in a
sequence overlay format in Figures S2 and S3. As expected,
the ID AF1/NTD and hinge domains of the receptors afforded
little protection to hydrogen/deuterium (H/D) exchange whereas
the folded globular DBD and LBD contain regions with significant
protection to solvent exchange. Representative deuterium build-
up plots for peptides from AF1/NTD show that, at the earliest
time point measured (10 s), their backbone amide hydrogens
are near fully exchanged with solvent (Figure 1). The conforma-
tional flexibility of TBPc, expressed in bacterial cells and purified
as previously described (Kumar et al., 2013), was also examined
by HDX-MS. TBPc is a folded globular structure, and thus most
sequence regions are significantly protected from solvent ex-
change. However, TBPc contains regions that are highly dynamic
and not protected to exchange (Figure S4).
Influence of TBPc Interaction on Conformational
Flexibility of Intact PR Liganded with Hormone Agonist
Next, we utilized differential HDX-MS to investigate the effect of
TBPc interaction on conformational flexibility of the hormone
agonist (R5020)-occupied intact receptor by comparing ex-
change kinetics in peptide regions of either PR-A or PR-B in
the absence (apo) and presence of TBPc. Interaction of
agonist-liganded PR-B with TBPc did not result in significant
changes in HDX in any region of AF1/NTD detected. However,
perturbations in exchange kinetics were observed in the
carboxyl terminal LBD of the receptor. Specifically, regions in
the LBD including (helix 1) H1 (aas 680–690), H9 and H10 (aas
850–870), and H12 showed reduced solvent exchange upon
interaction with TBPc. The deuterium build-up curves of selected
peptides along with the differential exchange data overlaid onto
the LBD crystal structure are shown in Figure 2A. AF2 is a well-
structured protein fold composed of helices 3–5 and 12 of the
LBD that forms a pocket for complementary binding of LXXLL
motifs of coactivators. Conformational positioning of H12 is crit-
ical for ligand-agonist-dependent activation of AF2. The stron-
gest effect of TBPc on stabilizing deuterium exchange kineticsreserved
Figure 1. Solution State Conformational Flexibility of Full-Length PR-B
Agonist (R5020)-bound full-length PR-B was analyzed by hydrogen deuterium exchange studies and the average percentage of deuterium incorporation across
six different time points (0, 10, 30, 60, 300, 900, and 3,600 s) is overlaid onto the crystal structure of PR-LBD (PDB ID: 1A28) and PR-DBD (PDB ID: 2C7A). The
color is according to the color code at the bottom of the figure. The hinge region and N-terminal domain are represented by schematics due to lack of atomic
structure. Representative peptide deuterium build-up curves from each domain are indicated at top. Error bars are plotted using GraphPad Prism software and
computed by HDX WorkBench software (Pascal et al., 2012).
Structure
HDX of TBP PR activationin the LBD was with peptides in H12, suggesting that TBPc
influences this critical region of PR either directly or indirectly
through allosteric interactions or through physical interactions
between N and C terminus of intact PR. Similar effects of
TBPc were observed on stabilizing exchange kinetics of H12
in PR-A (Figure 2B). Figure 2C shows a comparative view of
H12 stabilization in agonist-bound PR-A and PR-B upon TBPc
binding.
In previous reports, TBPc interaction with NTD of PR and
other SRs was demonstrated to induce an increase in second-
ary structure as detected by circular dichroism spectroscopy
and tertiary folding by fluorescence emission and partial prote-
olysis (Kumar et al., 2004, 2013; Kumar and Thompson, 2012).
Therefore, the failure to observe significant changes in HDX
kinetics within AF1/NTD upon interaction with TBPc was some-
what unexpected but may be due in part to the highly dynamic
nature of this domain. The deuterium build-up curves from
NTD (Figure 1) show most of the amide hydrogens are fully
exchanged at the earliest time point (10 s) measured. Thus, it
is possible that helical structures or tertiary folding detectedStructure 22by other methods within the NTD upon interaction with TBPc
(Khan et al., 2012; Kumar et al., 2013) interconverts to unstruc-
tured conformers at a time scale faster than 10 s. This phenom-
enon of transient ‘‘coupled folding and binding’’ process, where
an intrinsically disordered protein (IDP) undergoes disorder-
order transition upon interaction with a folded binding partner,
has been reported (Wright and Dyson, 2009). Previously, we re-
ported a strategy to characterize the transient protein-protein
interaction involving an IDP and its folded binding partner by
lowering the exchange pH and in turn expanding the time win-
dow to the millisecond level (Goswami et al., 2013). Appling a
similar approach here (interaction tested at pH 6.0) did not
result in a perturbation in HDX kinetics upon TBPc interaction
for any peptide detected from the AF1/NTD of hormone
agonist-bound full-length PR. It is possible that the affinity be-
tween PR and TBPc of 0.17 mM at pH 7.5 (Kumar et al., 2013)
is reduced further at pH 6.0. Another possibility is that the
sequence region that undergoes change in conformation may
be in a region that is not covered by MS/MS sequencing in
HDX experimental conditions (Figure S1). To further address, 961–973, July 8, 2014 ª2014 Elsevier Ltd All rights reserved 963
Figure 2. Agonist-R5020-Bound Full-Length PR when Interacted with TBPc Shows Stabilization at the C-Terminal LBD
(A) Agonist (R5020)-bound PR-B isoform when interacted with TBPc shows protection from exchange at several regions in LBD as depicted by schematic
representations. The average percentage of deuterium uptake values across six different time points is overlaid (color coded) onto LBD atomic structure (PDB ID:
1A28). The color is according to the color bar at the bottom of the figure. The representative deuterium build-up curves of protected regions of the LBD, including
the helix 12, is shown also.
(B) Schematic representation along with atomic structure (LBD) overlay and deuterium build-up curve of agonist-bound full-length PR-A and TBPc interaction.
(C) Comparison of deuterium uptake of AF2 regions in agonist-bound PR-B and PR-A interaction with TBPc after 900 s exposure to heavy water. Asterisks
indicate significant differences as calculated by the processing software (Pascal et al., 2009).
(D) HDX footprint of truncated agonist-bound PR-B (233–933)-TBP interaction and corresponding deuterium build-up curve.
Error bars are plotted using GraphPad Prism software and computed by HDX WorkBench software (Pascal et al., 2012).
Structure
HDX of TBP PR activationthis, we used a fragment of PR with truncation of NTD to aa
233 that is a shortened version of PR-A lacking an additional
68 aa from the N terminus. Differential HDX-MS was performed
with this 233-PR in the presence and absence of TBPc. TBPc
interaction failed to affect exchange in any regions of NTD
and resulted in protection to solvent exchange in AF2, with
the magnitude of protection being similar to that observed for
TBPc interaction with PR-A (Figure 2D). Similarity of results
with PR-A and 233-PR further emphasizes the importance of
the N-terminal sequence of PR-B as responsible for stronger
effect of TBPc on structural flexibility in the AF2 LBD and that
failure to detect perturbation in NTD is likely due to transient
nature of stabilized structure.964 Structure 22, 961–973, July 8, 2014 ª2014 Elsevier Ltd All rightsTBP Interaction with Antagonist Liganded PR
Next, we investigated the interaction of TBPc with antagonist-
bound PR. Previous crystallography and other protein biophysi-
cal methods have shown a significant change in conformation
of H12 of PR LBD upon binding the antagonist RU486 versus
hormone agonist (Raaijmakers et al., 2009; Vegeto et al., 1993;
Weigel et al., 1992). Interestingly, TBPc interaction with RU486-
liganded PR did not result in changes in the HDX kinetics in
H12or other helices of theLBD (Figures 3Aand3B).However, un-
like that observed for agonist-bound receptor, TBPc interaction
with RU486-liganded PR resulted in a slight but statistically sig-
nificant increase in solvent exchange in the region containing
aas 319–328 within the AF1/NTD of both PR-A and PR-B. Thisreserved
Figure 3. Antagonist-RU486-Bound Full-Length PR Interaction with TBPc
Antagonist-bound full-length PR-B (A) and PR-A (B) when interacted with TBPc showed slight destabilization at the N-terminal domain. Corresponding build-up
curves are shown with the schematic representation. Error bars are plotted using GraphPad Prism software and computed by HDXWorkBench software (Pascal
et al., 2012).
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HDX of TBP PR activationincrease in solvent exchange likely results from a rearrangement
of hydrogen bonding in this region upon interaction with TBPc.
Together, these results indicate that antagonist (RU486) binding
with PR blocks the allosteric communication between the NTD-
bound TBPc with AF2/LBD.
HDX of TBPc in the Presence and Absence of PR
Results from HDX analysis of the isolated AF1/NTD of PR in
the presence and absence of TBPc failed to detect any foot-
print on NTD and hence was consistent with the data obtained
using full-length receptor (Figure S5). Therefore, we investi-
gated the impact of AF1/NTD interaction on the conformational
flexibility of TBPc by analyzing the differential HDX kinetics of
TBPc in the presence and absence of these domains. These
experiments were performed with both isolated NTDs and
full-length receptors. Results demonstrate that the isolated
AF1/NTDs of PR-A and PR-B interact directly with TBPc, with
the AF1/NTD of PR-B inducing more stabilization of TBPc
when compared to AF1/NTD of PR-A (Figures 4A and 4B).
The region of TBPc containing aas 243–253 was stabilized by
both NTDs; however, interaction with PR-B AF1/NTD resulted
in additional regions being protected from solvent exchange
(aas 275–290), suggesting that AF1/NTD of PR-B makes a
stronger interaction with TBPc as compared with the NTD of
PR-A. Full-length PR-B induced greater perturbation of ex-
change on TBPc than PR-A (Figures 4C and 4D), an observation
that is consistent with HDX data obtained on the isolated AF1/
NTDs. However, closer inspection of the data shows additional
regions within TBPc are influenced in the presence of full-length
PR-B as compared to its isolated AF1/NTD, suggesting that
there are contributions from other regions of PR-B in binding
to TBPc.
Isolated PR-LBD Does Not Interact with TBPc
The observation that TBPc alters solvent exchange in both AF1/
NTD and AF2 (LBD) in the intact receptor encouraged us to
investigate if the LBD alone can interact with the TBPc and ifStructure 22so whether this interaction can alter conformation in AF2/H12.
To this end, isolated PR-LBD liganded with R5020 was analyzed
by HDX in the presence and absence of TBPc. As shown in Fig-
ures 5A and 5B, no statistically significant changes in HDX
kinetics were observed in either the PR-LBD or TBPc. These
data indicate either a lack of direct physical interaction of TBPc
with the LBD or that this interaction is not sufficient for altering
conformational flexibility of either LBD/AF2 or TBPc. In previous
studies with isolated PR-LBD, we were unable to detect direct
binding with TBPc (Kumar et al., 2013). These data collectively
suggest that TBPc only influences the flexibility of AF2 in the
context of the full-length PR and that there is no direct TBPc-
AF2 interaction.
Limited Proteolysis Analysis of Intact PR versus Isolated
Domains Confirms that Conformational Change Is
Dependent upon TBPc Interaction with the NTD
Previously, we have shown that, when bound to TBPc, the iso-
lated AF1/NTD of PR is protected against limited proteolysis,
suggesting that TBPc binding induces a more compact tertiary
structure in AF1/NTD (Kumar et al., 2013). To determine the influ-
ence of TBPc interaction on folding of the NTD and other
domains in the context of full-length PR, experiments were
extended to include limited proteolysis by trypsin of full-length
PR-A and isolated PR-LBD and NTD in the absence and pres-
ence of TBPc. As shown by Coomassie-stained SDS gels, iso-
lated PR-NTD was highly susceptible to proteolysis, resulting
in nearly complete degradation with little intact NTD remaining
(Figure 6A; compare lanes 2 and 6). PR-A also showed a high
susceptibility to proteolysis, except for a protected band corre-
sponding to the size of LBD (Figure 6A; compare lanes 1 and
5). The isolated PR-LBD and TBPc are highly resistant to limited
proteolysis (Figure 6A; compare lanes 3 and 7 and lanes 4 and 8,
respectively), consistent with stable globular structure of these
polypeptides. Limited proteolysis of mixtures of PR-A or PR-
NTD and TBPc resulted in some residual intact PR-A and NTD
plus smaller fragments not detected by digestion with either, 961–973, July 8, 2014 ª2014 Elsevier Ltd All rights reserved 965
Figure 4. Stabilization of TBPc Structure upon Interaction with Isolated NTD and Agonist-Bound Full-Length PR
TBP shows protection from exchange when interacted with isolated NTD of PR-B (A), NTD of PR-A (B), agonist-bound full-length PR-B (C), and agonist-bound
full-length PR-A (D). Regions of protection are represented by schematics, and the average percentage of deuterium uptake values across six different time
points is overlaid (color coded) onto the TBPc crystal structure (PDB ID: 1TGH) according to the color bar at the bottom of the figure. The deuterium build-up
curves are shown below the atomic models. FL, full length. Error bars are plotted using GraphPad Prism software and computed by HDX WorkBench software
(Pascal et al., 2012).
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HDX of TBP PR activationthe PR-A or PR-NTD alone (Figure 6A; lanes 9 and 10). To deter-
mine whether protected fragments generated from the PR-
A:TBPc mixture were coming from the PR-NTD or LBD, tryptic
digests were also analyzed by immunoblotting with monoclonal
antibodies (clones 1294 and 636) to different epitopes within the
PR-NTD (Figure 6B, upper and middle panels) or the C terminus
of PR-LBD (clone 10A9; Figure 6B, lower panel). Digests of PR-A
in the absence of TBPc showed a few fragments larger than LBD
that are reactive with NTD-specific monoclonal antibodies
(mAbs) (1294 and 636) plus a predominant protected protein
band the size of the LBD (27 kDa) that was reactive only with
the C-terminal-specific mAb (10A9; Figures 4 and 6B). As ex-
pected, digests of NTD alone generated only trace protected
bands reactive with NTD-specific mAbs and none that are
reactive with the LBD specific mAb (Figure 6B; lane 5). When
PR-A or PR-NTD and TBPc were mixed together, several
different protected PR fragments were detected with the PR-
NTD-specific mAbs and the patterns were distinct, with each
antibody indicating that multiple sites within the NTD change
their accessibility to trypsin in the presence of TBPc (Figure 6B;
compare lanes 4 and 7 and 5 and 8, respectively). Protection
against partial proteolysis indicates that the NTD folds into a
more compact conformation in the context of intact PR-A
when complexed with TBPc. Analysis of PR-A digests in the966 Structure 22, 961–973, July 8, 2014 ª2014 Elsevier Ltd All rightspresence TBPc with the PR-LBD-specific mAb (10A9) showed
an increase in relative amount of intact PR-A, a stronger pro-
tected band corresponding to LBD, plus several predominant
unique fragments between the size of intact PR and the LBD
not detected in the absence of TBPc (Figure 6B; compare lanes
4 and 7). As expected, no bands were detected with the LBD-
specificmAb (10A9) with digests of theNTD either in the absence
or presence of TBPc (Figure 6B; lanes 5 and 8). These results are
consistent with regions of both the NTD and LBD undergoing
protection from limited proteolysis when intact PR-A is com-
plexed with TBPc.
We previously showed that TBPc directly binds to NTD and not
LBD in vitro (Kumar et al., 2013); therefore, we carried out
another set of experiments to confirm that the conformational
changes observed in the PR-LBD are as a result of direct NTD-
TBPc binding in the full-length receptor. Because no detectable
cleavage of PR-LBD alonewas detected under conditions above
(Figures 6A and 6B), we carried out limited tryptic digestion of
PR-LBD with and without TBPc at room temperature for 10, 15,
and 20 min to allow a higher degree of digestion and resolved
the products of digestion by immunoblot with the PR-LBD-
specific antibody. As expected, a strong reaction for intact
PR-LBD was seen with the antibody (Figure 6C; lane 1) with no
reaction with TBPc. Under these conditions, several smallerreserved
Figure 5. LBD of PR Shows No Significant Interaction with TBPc by Itself
Differential HDX data of agonist-bound PR-hinge-LBD region with TBPc (A) and vice versa (B) showed no significant interactions. The color coding is according to
the color bar at the bottom of the figure.
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HDX of TBP PR activationprotected fragments of PR-LBD were generated by limited
digestion at each time point and there were no evident differ-
ences in the patterns of LBD cleavage in the absence or
presence of TBPc (Figure 6C). These results demonstrate that
protection from proteolysis in the LBD in the presence of TBP
occurs only with intact PR-A and not with the isolated LBD
(Figure 6B, lower panel), indicating this effect on structure in
the LBD is dependent on NTD-TBPc interaction and an interdo-
main communication.
DISCUSSION
The strategy for the development of structure-based SR modu-
lators has focused largely on ligand control of AF2, despite the
fact that the AF1/NTD region of SRs contribute significantly to
the receptor’s transcriptional activity, and functional synergy be-
tween AF1 and AF2 is essential to SR-mediated target gene
regulation. This is not surprising due to the limited knowledge
about the structure and conformational flexibility of AF1-AF2
interaction within full-length SRs. Similarly, there is lack of struc-
tural insight into coregulatory protein interactions with AF1/NTD.
It is generally thought that the ID nature of AF1/NTD enables this
region of the receptor to adapt different structures depending on
the context of the interacting partner. This structural plasticity
likely contributes to the functional diversity of the receptor and
may provide a strategy to modulate target-gene-promoter- or
tissue-specific effects.
Previous reports demonstrate that TBPc binding with the NTD
of steroid receptors induces secondary structure within AF1/
NTD by coupled binding and folding mechanism (Fischer
et al., 2010; Khan et al., 2011; Wa¨rnmark et al., 2001). BasedStructure 22on deletion mutation experiments, a subregion of PR-AF1/
NTD (aas 350–428) has been identified to undergo disorder-or-
der conformational transition upon its interaction with TBP, and
in cell transfection assays, this subregion was also required for
TBPc enhancement of AF1/NTD-dependent transcriptional ac-
tivity (Kumar et al., 2013). In addition to independent effects of
TBP on structure and function of the isolated PR-NTD, effects
of TBP on hormone-dependent AF2 activity in the context of
full-length PR were previously observed. With a constitutively
active two-domain PR-DBD/AF1-NTD construct that lacks
LBD/AF2, deletion of aas 323–427 of the NTD completely abro-
gated TBP stimulation of AF1/NTD-mediated transcriptional
activity, whereas deletion of this same region in full-length
PR-B only partially reduced TBP-dependent hormone-induced
transcriptional activation (Kumar et al., 2013). These functional
data suggested to us that TBP-induced folding of the NTD
has the potential to mediate an allosteric interdomain inter-
action, thus prompting HDX-MS analysis to further explore
this question.
HDX-MS has been used to probe the conformational flexibility
of intact multidomain proteins in solution, even in the absence
of a high-resolution atomic structure, and has the potential to
detect long-range allosteric effects (Zhang et al., 2011). In this
study, we applied HDX to probe the conformational flexibility
of intact PR-A and PR-B. As expected, the HDX results
show that AF1/NTD of both PR isoforms is highly dynamic as
compared to the DBD and LBD for both agonist- and antago-
nist-bound receptor. In both receptor isoforms, the hinge region
appears to be unstructured as well, as determined by rapid
deuterium incorporation in peptides representative of this
domain. These observations are consistent with another report, 961–973, July 8, 2014 ª2014 Elsevier Ltd All rights reserved 967
Figure 6. Folding NTD in the Context of Full-Length PR-A in the Presence of TBPc as Detected by Protection against Partial Proteolysis
Purified PR-A, PR-NTD, PR-LBD, TBPc, or an equal molar mixture of PR-A:TBPc, PR-A NTD:TBPc, and PR-LBD:TBPc proteins were subjected to limited
proteolysis with trypsin, and samples were analyzed by Coomassie blue-stained SDS-PAGE or by immunoblotting.
(A) Coomassie-stained SDS-PAGE.
(B) Immunoblotting of limited proteolytic products derived from either full-length PR-A or PR-A NTDwith antibodies (1,294 and 636) specific to distinct epitopes in
the NTD or the C-terminal LBD (10A9).
(C) Immunoblotting with the C-terminal mAb (10A9) of limited proteolytic products generated from the isolated PR-LBD at different time points indicated
(0–20 min).
Structure
HDX of TBP PR activationon full-length nuclear receptors (Chandra et al., 2008). Our pre-
sent study shows that full-length PR-B (bound to hormone
agonist) has higher degree of stabilization at helix 12 and
more perturbation sites compared to PR-A upon interaction
with TBPc (Figures 2A–2C). Isolated NTDs of PR-A and PR-B
follow the same norm (Figures 4A and 4B). Moreover, when
the first 232 aa of PR-B NTD is deleted, it shows a more PR-
A-like interaction with TBP (Figure 2D). Considering all these
observations of higher global protection in PR-B-TBPc inter-
actions, our HDX study supports previous findings that PR-B
is the dominant transcription activator and acts through a
distinct structural conformation of the NTD of B isoform than
that of the PR-A isoform (Bain et al., 2001; Hill et al., 2012;
Tung et al., 2006).
Despite the fact that TBPc interaction with isolated AF1/NTDs
of PR (and other SRs) has been demonstrated to induce a stabi-
lization of secondary helical structure and folding by other bio-
physical methods, we were not able to detect TPBc-dependent
protection to solvent exchange in AF1/NTD in the context of
either the intact PR (Figures 2 and 3) or the isolated NTD (Fig-
ure S5). This apparent discrepancy is likely due to the extreme
flexibility and disorder of the NTD and to the transient nature of
TBPc-induced folded structures that may not be detectable in968 Structure 22, 961–973, July 8, 2014 ª2014 Elsevier Ltd All rightsthe time frame of the HD exchange kinetics. Interaction of the
TIF2 coactivator with AF1 of glucocorticoid receptor (GR) gave
similar results wherein HDX-MS was unable to detect changes
in conformational flexibility, whereas other biophysical methods
detected structural changes (Khan et al., 2012). Interestingly, we
were able to detect perturbation in HDX kinetics of TBPc upon
interaction with either the isolated AF1/NTD or full-length PR
(Figures 4A and 4B). Additionally, both full-length PR-B and the
isolated NTD of PR-B gave stronger interactions and effects on
stabilizing structural conformations of TBPc than either intact
PR-A or isolated NTD, respectively, of PR-A (Figure 4). These re-
sults indicate that the AF1/NTD can affect structural conforma-
tion of an interacting protein and may be a mechanism by which
the intrinsically disordered AF1/NTD can affect activity of core-
gulatory proteins associated with receptors. Another finding of
this study was that TBPc interaction mediated stabilization of
AF2/LBD but only through interaction with NTD of the intact PR
occupied with hormone agonist. Additionally, the magnitude of
perturbation of AF2 conformation and number of protected
sites was greater with PR-B than PR-A (Figure 2). Consistent
with previous reports that TBPc binds only to NTD and not
with LBD (Kumar et al., 2013), no change in HD exchange
kinetics was observed with either an isolated PR-LBD (+ hinge)reserved
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HDX of TBP PR activationor TBPc when incubated together (Figure 5). With intact PR
(either isoform) bound to the hormone antagonist (RU486),
TBPc-induced perturbation of AF2/LBD was prevented and
unique perturbation of a short region between aas 319 and 328
within AF1/NTD was observed (Figure 3). These data collectively
support the conclusion that TBP interaction with AF1/NTD im-
pacts the AF2 surface via long-range allostery or that binding
TBP alters the proximity of AF1/NTD to AF2/LBD within the
intact receptor. Physical interaction between AF1 and AF2,
both in vivo and in vitro, has been reported before (Tetel et al.,
1999), resulting in a functional synergy between AF1 and AF2
that is an essential component of SR-mediated target gene
regulation (Chen et al., 2006; Choudhry et al., 2006). This
synergy is believed to be mediated by interdomain allosteric
pathways that may involve the conformation flexibility of the
NTD but through mechanisms that remain undefined experi-
mentally (Hilser and Thompson, 2011). Our limited proteolysis
experiments further support HDX results and this hypothesis
(Figure 6).
Hormone agonists as well as the antagonist RU486 induce
dimerization and binding of PR to consensus progesterone
response element (PRE) DNA. However, PR bound to target
DNA in the presence of RU486 has impaired transcription ac-
tivity due to an altered conformation in PR that does not permit
optimal recruitment of coregulatory proteins (Hill et al., 2012).
Ligand-dependent dimerization of PR in solution is thought
to occur as a requisite step prior to DNA binding. Although
controversial because the dimerization constant for purified
PR in solution is in the mM range above the concentration of
PR in most cells (Connaghan-Jones et al., 2006; Heneghan
et al., 2005), ligand-induced dimerization independent of
DNA binding has been shown in cell-based assays (Carbajo
et al., 1996; Hill et al., 2012; Tetel et al., 1997). The PR dimer
interface in the absence of DNA involves surfaces in both the
NTD (Bain et al., 2001; Tetel et al., 1997) and the LBD (Williams
and Sigler, 1998). Crystal structure of the PR-LBD showed
dimerization to be mediated by helices 10 and 11 (Williams
and Sigler, 1998), but sequences in the NTD have not been
defined. An additional DNA-dependent dimerization interface
is present in the DNA-binding domain that functions to stabilize
receptor dimers upon binding DNA (Hill et al., 2012). HDX
analysis of full-length PRs in the present study was performed
in the absence of DNA with purified PR in a dimeric form.
Therefore, our results reflect conformational flexibility of
preformed PR dimers and do not provide insight into dimer-
ization process. HDX-MS experiments for analysis of solu-
tion dimerization will require isolation of PR monomers and
in vitro conditions to promote monomer-dimer assembly.
DNA interaction has been demonstrated to induce changes
in structural conformation in either the NTD or LBD/AF2s of
steroid receptors. Moreover, different target DNA sequences
have been observed to induce distinct conformations, indi-
cating DNA can act as a regulatory ligand for steroid receptors
(Hill et al., 2012; Kumar and Thompson, 2012; Meijsing et al.,
2009). In the present study, we did not analyze the effect
of DNA on conformational flexibility of PR. Studies focused
on the effects of hormonal ligands and a protein-binding
partner. It will be important to perform differential HDX-MS
analysis of PR-DNA complexes to gain a more completeStructure 22assessment of the structural state of transcriptionally active
receptors.
Based on the results from the studies presented here, we
developed a model for how TBP interaction with the flexible
NTD can allosterically mediate structural rearrangement in the
NTD and the LBD to potentially affect synergistic transcriptional
activation between AF1 and AF2 modulated by ligand (Figure 7).
Although HDX-MS analysis was done only with PR dimers in
solution, DNA is included in the model as the convention for
PR as a sequence-specific DNA-binding transcription factor.
Both hormone agonists and the antagonist RU486 are known
to induce dimerization and binding of PR to progesterone
response element DNA. Upon binding DNA PR recruits assem-
bly of coregulatory proteins required for transcriptional activa-
tion and due to distinct conformations in PR, coregulators are
different in the presence of hormone agonist and antagonist.
HDX results provide information on potential allosteric regula-
tion of LBD/AF2 through TBP-PR NTD interaction. In the
presence of hormone agonist, TBP-PR interaction results in
structural reorganization of both the NTD and LBD/AF2. In the
presence of the antagonist RU486, TBP interaction resulted in
a small destabilization of NTD and failed to mediate the interdo-
main communication that results in structural reorganization of
LBD/AF2.
An emerging picture is that the entire SR-signaling spectrum
involves allosteric interactions between AF1/NTD and AF2/LBD
surfaces for coregulatory protein interactions. It has also been
suggested that the tissue-specific residual activity of selective
SRMs used to therapeutically target SRs is mediated primarily
via AF1 and that the relative functional importance of AF1 may
be decided by specific SRM-induced conformational changes
in either LBD or transmitted allosterically to the NTD (Berry
et al., 1990; Halachmi et al., 1994; Lonard and O’Malley, 2012;
Simons, 2010; Wu et al., 2005). Our present studies support
this notion, as HDX analysis of RU486-bound full-length PR:TBP
complex shows that antagonist both negates the TBP impact on
AF2 flexibility and destabilizes a region within AF1/NTD that was
not detected with intact PR occupied by hormone agonist
(Simons et al., 2014; Figure 3). There is precedent for RU486
promoting a structural conformation in the AF1/NTD of PR
distinct from that of hormone agonist. Partial agonist activity of
RU486 mediated by a coactivator that binds the PR-DBD
and allosterically affects NTD structure was shown to require
sequence regions within NTD (aas 327–427) that are not required
for functional coactivator response in the presence of hormone
agonist (Wardell et al., 2010).
The significance of these findings lies in the possibility of
therapeutically targeting AF1/NTD surfaces directly or in-
directly, by allosteric modulations, to achieve tissue-restricted
effects. Because TBP is a common binding partner for AF1/
NTD of all SRs and does not bind to the AF2/LBD, yet leads
to conformational changes in the AF2/LBD, we hypothesize
that TBP-induced disorder-order transition opens AF1/NTD
protein surfaces for its interactions with specific coactivators.
Consistent with this concept, we previously reported that
structural reorganization of AF1/NTD of both GR and PR
induced by TBP, enhanced binding of SRC-1 to AF1/NTD,
and TBP and SRC-1 acted synergistically to functionally stimu-
late AF1/NTD-dependent transcriptional activity (Khan et al.,, 961–973, July 8, 2014 ª2014 Elsevier Ltd All rights reserved 969
Figure 7. A Model of TBP-PR-NTD Interac-
tion to Allosterically Mediate Structural
Changes in LBD/AF2
Both hormonal agonist and antagonist promote
dimerization and binding of PR to progesterone
response element (PRE) target DNA. Once DNA
bound, receptor dimers assemble a multiprotein
complex of coregulators, which differ for an
agonist versus antagonist due at least in part to
distinct conformations in the LBD/AF2. In the
presence of agonist, TBP binding to the NTD
results in conformational rearrangements in the
NTD and in the LBD/AF2 through allosteric regu-
lation. These structural rearrangements facilitate
the binding and assembly of other coactivators
at either LBD/AF2 or AF1 in the NTD. In the
presence of antagonist, TBP binding with NTD
resulted in a slight destabilization of NTD structure
and the interdomain communication with LBD/AF2
was lost.
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HDX of TBP PR activation2011; Kumar et al., 2013). Further understanding the structural
and functional consequences of the AF1/NTD-TBP interaction
sites may provide potential avenues to modify both AF1 and
AF2 activities simultaneously. This level of control is needed
for additional selectivity to target cell-tissue-specific gene regu-
lations in current endocrine-based therapies that could comple-
ment or replace existing SRMs’ actions. Targeting ID proteins
by small molecules/peptides to block protein-protein interac-
tions is a rapidly evolving field, and the above findings suggest
that compounds that bind to NTD/AF1 could be promising mol-
ecules for SR-based therapeutics (Dunker and Uversky, 2010;
Ferreon et al., 2013; Simons et al., 2014). Drugs have been
defined that interfere with intrinsic disorder-to-order transition
induced by a binding protein by directly interacting with ID
regions of the transcription factor (Dunker and Uversky, 2010).
Meaningful screens for small molecules that could modify
AF1/NTD-TBP binding may provide the additional selectivity
needed to target SR-selective genes and thereby reduce the
number of undesirable side effects in current endocrine-based
cancers.EXPERIMENTAL PROCEDURES
Reagents, Chemicals, and Purified Proteins
High-performance liquid chromatography (HPLC)-grade H2O, D2O (9.9%),
acetonitrile, formic acid, isopropanol, Tris, and NaCl was purchased from
Sigma-Aldrich, and trifluoroacetic acid (TFA; sequanal grade) was obtained
from Pierce. The procine pepsin-immobilized POROS 20 AL beads (Applied
Biosystems) of particle size 20 mmwere used to pack immobilized pepsin col-
umns. Full-length PR-A and PR-B as well as isolated PR NTD domains were
expressed from baculovirus vectors as recombinant proteins in Sf9 insect cells970 Structure 22, 961–973, July 8, 2014 ª2014 Elsevier Ltd All rights reservedand purified as previously described with >95%
purity at a concentration range of 10–20 mM
(Kumar et al., 2013; Wardell et al., 2005). By size-
exclusion chromatography (S-200 column), puri-
fied full-length PR-A and PR-B fractionated as a
single symmetrical peak with a retention volume
consistent with that of a PR dimer. For isolation
and purification of intact PR bound to either
hormone agonist (R5020) or antagonist (RU486),
ligands were added to Sf9 insect cell cultures for24 hr prior to cell harvest as previously described (Wardell et al., 2005). The
C-terminal core DNA-binding domain (aas 159–339) of human TATA-binding
protein (TBPc) was expressed from a pET-21d bacterial expression vector
and purified as previously described (Kumar et al., 2013). Glutathione S-trans-
ferase-tagged PR-LBD (675–693) was purchased from Invitrogen (catalog
no. P2899).Hydrogen/Deuterium Exchange and Mass Spectrometry
Solution-phase amide HDX was carried out with a fully automated system as
described previously (Chalmers et al., 2006; Goswami et al., 2013). Briefly,
4 ml of 10 mM full-length PR or PR constructs or TBPc was diluted to 20 ml
with D2O-containing HDX buffer and incubated at 4
C for 10 s, 30 s, 60 s,
900 s, or 3,600 s. Following on exchange, unwanted forward or back exchange
was minimized and the protein was denatured by dilution to 50 ml with 0.1%
(v/v) TFA in 5 M urea (held at 1C). Samples were then passed across an
immobilized pepsin column at 50 ml min1 (0.1% v/v TFA; 15C); the resulting
peptides were trapped on a C8 trap cartridge (Hypersil Gold; Thermo Fisher
Scientific). Peptides were then gradient-eluted (4% [w/v] CH3CN to 40%
[w/v] CH3CN and 0.3% [w/v] formic acid over 5 min at 2C) across a 1 3
50 mm C18 HPLC column (Hypersil Gold; Thermo Fisher Scientific) and elec-
trosprayed directly into an Orbitrap mass spectrometer (LTQ Orbitrap with
ETD; Thermo Fisher Scientific). Peptide ion signals were confirmed if they
had a MASCOT score of 20 or greater and had no ambiguous hits using a
decoy (reverse) sequence in a separate experiment using a 60 min gradient.
The intensity-weighted averagem/z value (centroid) of each peptide’s isotopic
envelope was calculated with the in-house developed software (Pascal et al.,
2012) and corrected for back-exchange on an estimated 70% recovery and
accounting for the known deuterium content of the on-exchange buffer. To
measure the difference in exchange rates, we calculated the average percent-
age deuterium uptake for say full-length PR following 10, 30, 60, 900, and
3,600 s of on exchange. From this value, we subtracted the average percent
deuterium uptake measured for the TBPc-bound PR (at 5:1 molar ratio).
For back-exchange correction, experiments were repeated with full deute-
rium controls (run in triplicate). Proteins were diluted to 10 mM, predigested
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HDX of TBP PR activationwith pepsin offline, and incubated at 37C for 16 hr with D2O containing
HDX buffer with the same ratio as the above-mentioned HDX experiments.
Then, 20 ml of aliquots were added to 30 ml of cold quench buffer and
subsequent sample analysis was carried out in automated fashion as
described for HDX samples (above), except no correction for estimated deute-
rium recovery was applied. Instead, the average percent deuterium values
from each triplicate sample was divided by the average percent deuterium
values from the full deuterium controls to correct for individual peptide back
exchange.
Limited Proteolysis
Three sets of partial proteolytic experiments were carried out. In the first set,
purified proteins (PR-A, PR-NTD, PR-LBD, TBPc, PR-A:TBPc, PR-NTD:TBPc,
and PR-LBD:TBPc mixture) were digested by using trypsin (Promega). Diges-
tionswere carried out at 4C for 15min by using a protein:enzymemass ratio of
100:1. Reactions were terminated by adding SDS loading buffer and placing
the sample tubes in boiling water for 5 min. The proteolytic digestion products
were resolved on SDS-PAGE followed by Coomassie blue R-250 staining. In
the second set, following digestion of PR-A, PR-NTD, TBPc, and PR-A:TBPc
and PR-NTD:TBPc mixtures, proteolytic digestion products were resolved
on SDS-PAGE and proceeded with immunoblotting with PR-NTD- or LBD-
specific antibodies. Mouse mAbs to human PR (clone no. 1294 and 636),
which detect distinct epitopes in the NTD (Press et al., 2002), and clone
10A9 (Immunotech) elicited against amino acids 922–933, which form the
extreme C terminus of the human PR, were used to detect the peptide
products of PR. In the third set, PR-LBD, TBPc, and PR-LBD:TBPc mixture
were digested with trypsin at room temperature for 10, 15, and 20 min and
proteolytic digestion products were resolved on SDS-PAGE followed by
immunoblotting with PR-LBD-specific antibody (10A9).
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